This is the case, for example, in non-small cell lung cancer (NSCLC) [75] (Table 1), and is consistent with other publications that have also found an association between CB2 receptor upregulation and cancer development and poorer survival, such as in squamous cell carcinoma of the head and neck [68], renal cell carcinoma [95] and HER2-positive breast cancer [47]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.